The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass

Phase 2

• Conditions: Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Coronary Artery Disease
• Interventions: Procedure: hemodialysis

• Registration Number: NCT01410617
• Lead Sponsor: Imam Khomeini Hospital

Brief Summary

Coronary artery disease is a major cause of death in patients with renal dysfunction Among patients who undergo coronary artery bypass grafting ,renal dysfunction is known To be a major predictor of in-hospital and remote mortality As little is known about the impact of non-dialysis-dependent renal dysfunction on short and mid term Outcomes following coronary surgery we have decided to investigate the effect of prophylactic Hemodialysis on the mortality and morbidity of the patients with ckd (stage 3,4 ) and compare these Effect with the control group

Detailed Description

Not available

Study Timeline

• Study Start: 2011-08
• Study First Submitted: 2011-08-03
• Study First Submitted QC: 2011-08-04
• Study First Posted: 2011-08-05
• Status Verified: 2013-03
• Last Update Submitted: 2013-03-25
• Last Update Posted: 2013-03-27
• Primary Completion: 2013-09
• Study Completion: 2013-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• 80<age>18
• ckd patients with stage 3,4
• CABG for the first time

Exclusion Criteria

• age<18
• previous CABG (coronary artery bypass grafting)
• AKI(acute kidney injury)
• dialysis patients

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
dialysis	hemodialysis	the patients who undergo 3 sessions prophylactic hemodialysis

Primary Outcome Measures

Name	Time	Method
morbidity	the morbidity during the time of hospitalization until discharge (baseline) and six month later	morbidity is defined as length of hospitalization,infection rate,duration of mechanical ventilation,bleeding complications,

Secondary Outcome Measures

Name	Time	Method
mortality	from the time of CABG (baseline) until six months later

Trial Locations

Locations (1)

Tehran Herat Center; 🇮🇷 Tehran, Iran, Islamic Republic of